Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Treatment of fungal pyelonephritis and ureterolithiasis with a subcutaneous ureteral bypass system and systemic antifungal medication in a cat.

ABSTRACT: PurposeWe describe a case of ureteral obstruction and fungal pyelonephritis in a cat. The case was managed successfully with a subcutaneous ureteral bypass (SUB) device and systemic antifungal medication.Case summaryA 9-year-old, male, neutered, domestic shorthair cat was referred for severe azotemia, ureteral obstruction, and sonographically identified progressive pyelectasia of the left kidney. A SUB device was placed. Cytology of the left kidney subsequently identified fungal organisms, and the cat responded clinically to treatment with fluconazole and supportive care. The cat survived for 11 months with intermittent fluconazole treatment.ConclusionFungal pyelonephritis should be considered as a possible concurrent diagnosis in cats with ureteral obstruction. The successful clinical outcome in this case suggests that treatment with SUB placement, antifungal medication, and supportive care could be an effective treatment strategy.

SUBMITTER: McQuitty RG

PROVIDER: S-EPMC6267714 | biostudies-other | 2018

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Subcutaneous ureteral bypass device placement in 81 cats with benign ureteral obstruction (2013-2018).

Project description:BackgroundBenign ureteral obstructions (BUOs) present a therapeutic challenge in cats.Hypothesis/objectivesThe purpose of this study was to determine the outcome and complications associated with placement of subcutaneous ureteral bypass (SUB) device in cats.AnimalsEighty-one client-owned cats (117 kidneys) with BUO treated by placement of a SUB.MethodsRetrospective study. Medical records of cats with BUO and treated by SUB device placement between 2013 and 2018 were reviewed. Outcome and complications were documented.ResultsHospital discharge rate was 94% (76/81). Serum creatinine on admission and at the time of discharge was 5.3 mg/dL (range, 1.2 to >15 mg/dL) and 2.1 mg/dL (range, 1.1-12.5 mg/dL), respectively. Luminal obstructions were documented in 17% (18/109) of the SUB devices of 16 cats discharged from the hospital. Infection was documented in 26% (20/76) of discharged cats. Kink of the device was documented in 10% (12/117) of devices. Time to luminal obstruction and kink were 204 days (range, 21-1678 days) and 58 days (range, 2-601 days), respectively. Fourteen of 81 (17%) cats required a revision surgery in order to restore patency of the device. At the time of writing, 53% (43/81) of cats were alive, with a mean survival time of 821 days (range, 1-2170 days) after surgery. Of those that died, 52% (20/38) died of urinary related causes.Conclusion and clinical importanceThis study suggests that SUB device placement is associated with good outcomes and could be considered for the treatment of BUO in cats.

| S-EPMC8692180 | biostudies-literature

Antifungal agents for the treatment of systemic fungal infections in children.

Project description:Traditionally, the mainstay of systemic antifungal therapy has been amphotericin B deoxycholate (conventional amphotericin B). Newer agents have been developed to fulfill special niches and to compete with conventional amphotericin B by virtue of having more favourable toxicity profiles. Some agents have displaced conventional amphotericin B for the treatment of specific fungal diseases. For example, voriconazole has emerged as the preferred treatment for invasive pulmonary aspergillosis. This notwithstanding, conventional amphotericin B remains a useful agent for the treatment of paediatric fungal infections. Knowledge of the characteristics of the newer agents is important, given the increasing numbers of patients who are being treated with these drugs. Efforts need to be directed at research aimed at generating paediatric data where these are lacking. The antifungal agents herein described are most often used as monotherapy regimens because there is no uniform consensus on the value of combination therapy, except for specific scenarios.

| S-EPMC3009569 | biostudies-other

Antifungal agents for the treatment of systemic fungal infections in children.

| S-EPMC3009580 | biostudies-other

Association of pretreatment with antifungal medication and fungal resistance in the mycotic ulcer treatment trial I.

Project description: Not available

| S-EPMC4962690 | biostudies-literature

Antifungal Combination Eye Drops for Fungal Keratitis Treatment.

Project description:Fungal keratitis (FK) is a corneal mycotic infection that can lead to vision loss. Furthermore, the severity of FK is aggravated by the emergence of resistant fungal species. There is currently only one FDA-approved formulation for FK treatment forcing hospital pharmacy departments to reformulate intravenous drug preparations with unknown ocular bioavailability and toxicity. In the present study, natamycin/voriconazole formulations were developed and characterized to improve natamycin solubility, permanence, and safety. The solubility of natamycin was studied in the presence of two cyclodextrins: HPβCD and HPγCD. The HPβCD was chosen based on the solubility results. Natamycin/cyclodextrin (HPβCD) inclusion complexes characterization and a competition study between natamycin and voriconazole were conducted by NMR (Nuclear Magnetic Resonance). Based on these results, several eye drops with different polymer compositions were developed and subsequently characterized. Permeability studies suggested that the formulations improved the passage of natamycin through the cornea compared to the commercial formulation Natacyn®. The ocular safety of the formulations was determined by BCOP and HET-CAM. The antifungal activity assay demonstrated the ability of our formulations to inhibit the in vitro growth of different fungal species. All these results concluded that the formulations developed in the present study could significantly improve the treatment of FK.

| S-EPMC9866460 | biostudies-literature

Fungal Bezoar: A Rare Cause of Ureteral Obstruction.

Project description:A 52-year-old male, with diabetes mellitus and alcoholic liver disease, presented to the Emergency Room for right flank pain of 3 days' duration, associated with dysuria. Physical examination revealed right flank tenderness with fever and hypotension; laboratory findings showed acute kidney injury and large blood and leucocytes in the urine. A CT abdomen and pelvis showed hydronephrosis of the right collecting system of a horseshoe kidney with air and hyperdense debris in the renal pelvis. Patient was treated for multisensitive Proteus mirabilis emphysematous pyelonephritis, and a right nephrostomy tube was inserted. Symptoms recurred in 4 weeks, and repeated urine culture grew Candida albicans and CT scan showed same high density material within the right moiety of the horseshoe kidney. Patient underwent ureteroscopy, and a white fluffy material was aspirated from the right renal pelvis. Pathology of the aspirate confirmed the presence of fungal balls. Patient was given 2 weeks of oral fluconazole. Fungal pyelonephritis is unusual and difficult to treat. Candida species is responsible for the clear majority of the cases. A fungus ball should be managed with surgical and medical therapy. This patient had an endoscopic procedure to remove the fungus ball and received fluconazole. His symptoms resolved and urine culture was done before termination of the treatment was negative.

| S-EPMC5540523 | biostudies-other

PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections.

Project description:Disease due to pulmonary Aspergillus infection remains a significant unmet need, particularly in immunocompromised patients, patients in critical care and those with underlying chronic lung diseases. To date, treatment using inhaled antifungal agents has been limited to repurposing available systemic medicines. PC945 is a novel triazole antifungal agent, a potent inhibitor of CYP51, purpose-designed to be administered via inhalation for high local lung concentrations and limited systemic exposure. In preclinical testing, PC945 is potent versus Aspergillus spp. and Candida spp. and showed two remarkable properties in preclinical studies, in vitro and in vivo. The antifungal effects against Aspergillus fumigatus accumulate on repeat dosing and improved efficacy has been demonstrated when PC945 is dosed in combination with systemic anti-fungal agents of multiple classes. Resistance to PC945 has been induced in Aspergillus fumigatus in vitro, resulting in a strain which remained susceptible to other antifungal triazoles. In healthy volunteers and asthmatics, nebulised PC945 was well tolerated, with limited systemic exposure and an apparently long lung residency time. In two lung transplant patients, PC945 treated an invasive pulmonary Aspergillus infection that had been unresponsive to multiple antifungal agents (systemic ± inhaled) without systemic side effects or detected drug-drug interactions.

| S-EPMC7765807 | biostudies-literature

Repeated spontaneous migration of ureteral stent in hemiplegia patient during ureteral stone treatment.

Project description:A 48-year-old man with a history of cerebral infarction presented with gross hematuria. The patient's limping accompanies twisting trunk on his walking. The diagnosis was right upper ureteral stone. Prior to Extracorporeal shockwave lithotripsy (ESWL) ureteral stent was inserted. After the second ESWL ureteral stent was displaced upwardly without patient's unknown. Retrograde intrarenal surgery (RIRS) was performed for both removal of ureteral stent and fragmentation of residual stone. Spontaneously, post RIRS ureteral stent was migrated upwardly to the same position. Ureteral stent migration is uncommon. Twisting walk may cause the position of ureteral stent upwardly.

| S-EPMC6562287 | biostudies-literature

Photodynamic antifungal activity of a superparamagnetic and fluorescent drug carrier system against antibiotic-resistant fungal strains.

Project description:Increased antimicrobial resistance demands the development of new antimicrobial agents with high potency. A wide variety of microbial systems are continuously subjected to mutations which ultimately results in antimicrobial resistance. The present study aimed at the fabrication of a nano drug delivery system which simultaneously is superparamagnetic, fluorescent, non-cytotoxic and antifungal. The developed system is an easily targetable and detectable tool owing to its superparamagnetic and fluorescent characteristics respectively. Superparamagnetic iron oxide nanoparticles stabilized by macromolecular starch have been incorporated into a fluorescently modified carrier system to get the final drug delivery system. The finally developed drug carrier system is found to be non-cytotoxic from the in vitro cytotoxicity studies performed against normal rat spleen cells. The photodynamic antifungal capability of the system was the premier concern of investigation of the present study. The antifungal studies were conducted against Histoplasma capsulatum and Trichophyton rubrum by well diffusion method and the results were compared with the activity of the antibiotic, griseofulvin. The minimum inhibitory concentration against each fungal strain was determined using broth dilution method.Graphic abstractSupplementary informationThe online version contains supplementary material available at 10.1007/s10570-021-04107-y.

| S-EPMC8325540 | biostudies-literature

Emerging Threats in Antifungal-Resistant Fungal Pathogens.

Project description:The use of antifungal drugs in the therapy of fungal diseases can lead to the development of antifungal resistance. Resistance has been described for virtually all antifungal agents in diverse pathogens, including Candida and Aspergillus species. The majority of resistance mechanisms have also been elucidated at the molecular level in these pathogens. Drug resistance genes and genome mutations have been identified. Therapeutic choices are limited for the control of fungal diseases, and it is tempting to combine several drugs to achieve better therapeutic efficacy. In the recent years, several novel resistance patterns have been observed, including antifungal resistance originating from environmental sources in Aspergillus fumigatus and the emergence of simultaneous resistance to different antifungal classes (multidrug resistance) in different Candida species. This review will summarize these current trends.

| S-EPMC4791369 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data